|
IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology, the ProSense System that destroys tumours by freezing, announced it has received a Notice of Allowance from the US Patent and Trademark Office for its patent application titled "Cryogen Pump". The patent will be in effect until February 2040 and was recently granted in the European Union and allowed in Japan.
"ProSense is gaining increasing commercial traction in the US in the indications for which it already has regulatory approval and reimbursement, as well as increased visibility in breast cancer following our October 2022 regulatory filing with the FDA. This Notice of Allowance in the US is very well timed to protect our intellectual property as we develop the next generation of cryoablation systems to perform minimally invasive procedures for new indications," stated Eyal Shamir, IceCure's chief executive officer.
The novel cryogenic pump enables IceCure to bring to market a new generation of cryoablation systems with a small footprint for a wide range of clinical applications. Moreover, this pump expands IceCure's portfolio of products with a broader range of thinner cryoprobes and catheters.
IceCure's novel cryogenic pump is submersible in liquid nitrogen, works in a closed circuit, enables temperature control of the cryoprobe, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill liquid nitrogen.
IceCure Medical Ltd. develops and markets ProSense, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumours (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.
|